Cellular immunotherapies represent a promising approach for the treatment of cancer.
Engineered adoptive cell therapies redirect and augment a leukocyte's inherent ability to
mount an immune response by introducing novel anti-tumor capabilities and targeting
moieties. A prominent example of this approach is the use of T cells engineered to express
chimeric antigen receptors (CARs), which have demonstrated significant efficacy against
some hematologic malignancies. Despite increasingly sophisticated strategies to harness …